Updated AAD Guidelines for Topical AD Treatment in Adults

18 Jan 2023 • "The Americal Academy of Dermatology(AAD) has unveiled new updated guidelines for the treatment of Atopic Dermatitis in Adults. The development updates the AAD's 2014 recommendations for managing AD with topical therapies, published almost 9 years ago. The new guidelines rate the existing evidence as ""strong"" for prescription moisturizers, topical calcineurin inhibitors, topical corticosteroids, and topical phosphodiesterase-4 (PDE-4) and Janus kinase (JAK) inhibitors. The guidelines also conditionally recommend the use of bathing and wet wrap therapy but recommend against the use of topical antimicrobials, antiseptics, and antihistamines. For the new guidelines, which were published online in the Journal of the American Academy of Dermatology, Dr. Sidbury, chief of the division of dermatology at Seattle Children's Hospital, guidelines cochair Dawn M. R. Davis, MD, a dermatologist at Mayo Clinic, Rochester, Minn., and colleagues conducted a systematic review of evidence regarding the use of nonprescription topical agents such as moisturizers, bathing practices, and wet wraps, as well as topical pharmacologic modalities such as corticosteroids, calcineurin inhibitors, JAK inhibitors, PDE-4 inhibitors, antimicrobials, and antihistamines. Next, the work group applied the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach for assessing the certainty of the evidence and formulating and grading clinical recommendations based on relevant randomized trials in the medical literature. Of the 12 recommendations made for adults with AD, the work group ranked 7 as ""strong"" based on the evidence reviewed, and the rest as ""conditional."" The ""strong"" recommendations include the use of moisturizers; the use of tacrolimus 0.03% or 0.1%; the use of pimecrolimus 1% cream for mild to moderate AD; use of topical steroids; intermittent use of medium-potency topical corticosteroids as maintenance therapy to reduce flares and relapse; the use of the topical PDE-4 inhibitor crisaborole, and the use of the topical JAK inhibitor - ruxolitinib.

Source: Medscape | Read full story"

Contact us


+91 9023-729662

Medflix Logo

© 2022 Plexus Professionals Network Pvt Ltd